According to the Company, detailed results will be presented at a medical meeting in 2025. A phase 3 trial evaluating tiragolumab in combination with Tecentriq ® (atezolizumab) in adults with PD-L1 ...

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks ...

(HealthDay News) — Exposure to certain antiseizure medications (ASMs) in utero is associated with an increased likelihood of neurodevelopmental diagnoses, according to a study published online Nov. 15 ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

Participants were randomly assigned to receive subcutaneous sotatercept or placebo every 21 days with background PAH therapy. The primary endpoint was the time to first confirmed morbidity or ...

Imkeldi is a liquid formulation of imatinib that utilizes proprietary technology to allow for accurate dosing and an alternative formulation to tablets.

Simufilam is an investigational oral small molecule that targets the filamin A protein. In the ReThink-ALZ study (ClinicalTrials.gov Identifier: NCT04994483 ), patients with confirmed mild or moderate ...

There was variation seen in coverage by jurisdiction and demographic characteristics, with younger adults and those without health insurance having the lowest coverage. (HealthDay News) — COVID-19, ...

Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...

The researchers used the Baltimore Longitudinal Study of Aging, a prospective cohort study of community-dwelling older adults.

No long-term cognitive effects of mHT were seen in the KEEPS Continuation study, about 10 years after completion of randomized treatment ...

The researchers found that postpartum depression prevalence doubled during the study period, increasing from 9.4% in 2010 to 19.0% in 2021. (HealthDay News) — Diagnosis of postpartum depression ...